Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. announced positive interim results from its U.S. Phase Ib trial of ASC30, a potentially first-in-class subcutaneous injection small molecule GLP-1R agonist. The trial demonstrated a 36-day half-life for one formulation, supporting less frequent administration, and showed a favorable safety profile with no serious adverse events. This advancement could enhance Ascletis’ positioning in the obesity treatment market, offering a novel therapeutic option with both oral and injectable formulations.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on the development of innovative drugs for the treatment of diseases such as obesity. The company specializes in creating small molecule therapeutics, with a particular emphasis on GLP-1 receptor agonists, and operates within the global pharmaceutical market.
YTD Price Performance: 147.51%
Average Trading Volume: 6,073,762
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.21B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.